We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Model System Allows Study of Cell Cycle Checkpoint Proteins

By LabMedica International staff writers
Posted on 01 Dec 2009
Print article
Cancer researchers have created a mouse model system that allows them to study cell cycle checkpoint proteins in healthy and cancerous mammary gland tissues.

Checkpoint proteins monitor the status of the cell genome and, in response to DNA damage, halt cell cycle progression and promote repair or apoptosis, thereby preventing mutation accumulation and suppressing tumor development. The checkpoint protein Hus1 associates with the proteins Rad9 and Rad1 to form the 9-1-1 complex, which localizes to DNA lesions and promotes DNA damage signaling and repair.

Attempts to genetically engineer mice to lack Hus1 failed, as complete inactivation of Hus1 resulted in embryonic lethality. Therefore, investigators at the Cornell University College of Veterinary Medicine (Ithaca, NY, USA) developed a system for regulated Hus1 inactivation in the mouse mammary gland to examine roles for Hus1 in tissue homeostasis and tumor suppression.

They reported in the Nov. 16, 2009, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) that Hus1 inactivation in the mammary epithelium resulted in genome damage that induced apoptosis and led to depletion of cells lacking Hus1 from the mammary gland. In cancerous tissue with an inactive form of the tumor-suppressor protein p53, there was a delay in the clearance of cells lacking Hus1 that caused the accumulation of damaged, dying cells in the mammary gland.

"Our work contributes to an important new understanding of cancer cells and their weaknesses," said senior author Dr. Robert Weiss, professor of molecular genetics at the Cornell University College of Veterinary Medicine. "The mutations that allow cancer cells to divide uncontrollably also make the cancer cells more dependent on certain cellular processes. We were able to exploit one such dependency of p53-deficient cells and could efficiently kill these cells by inhibiting Hus1. We have proven the power of inhibiting both pathways in normal tissue. Now we want to extend our knowledge to cancerous tissue and determine if the loss of Hus1 will impact the ability of cancers with p53 mutations to take hold and grow."

Related Links:
Cornell University College of Veterinary Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.